Zymeworks' Ziihera Shows Early Promise in HER2+ Breast Cancer Trial
Event summary
- Zymeworks' partner Jazz Pharmaceuticals will present four abstracts on Ziihera (zanidatamab-hrii) at the 2026 AACR Annual Meeting, including data from a Phase 2 trial in early-stage HER2+ breast cancer.
- In the NeoZanHER trial, zanidatamab demonstrated a 30% pathologic complete response rate (pCR) in patients with early-stage HER2+ breast cancer after six weeks of treatment.
- Additional presentations will explore zanidatamab's utility across HER2-expressing solid tumors and innovative biomarker-driven clinical trial designs.
The big picture
Zymeworks' Ziihera is emerging as a potential multi-tumor asset in the HER2-targeted oncology space. The Phase 2 data from the NeoZanHER trial suggests zanidatamab could carve out a niche in early-stage HER2+ breast cancer, expanding its addressable market beyond its current approvals. With multiple clinical trials underway and strategic partnerships in place, Zymeworks is positioning itself as a key player in the evolving landscape of HER2-directed therapies.
What we're watching
- Clinical Efficacy
- How zanidatamab's 30% pCR rate in HER2+ breast cancer will position it against existing therapies like trastuzumab deruxtecan.
- Expansion Strategy
- Whether Zymeworks can leverage these data to expand zanidatamab's indications beyond biliary tract and gastroesophageal cancers.
- Partnership Dynamics
- The pace at which Jazz Pharmaceuticals advances zanidatamab through its pipeline, given the Breakthrough Therapy and Fast Track designations.
Related topics